The US medical devices industry saw a drop of 13.4% in overall deal activity during June 2020, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 71 deals worth $2.5bn were announced in June 2020, compared to the 12-month average of 82 deals.
Venture financing was the leading category in the month in terms of volume with 41 deals which accounted for 57.8% of all deals.
In second place was M&A with 23 deals, followed by private equity with seven transactions, respectively accounting for 32.4% and 9.9% of overall deal activity in the country’s medical devices industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $1.7bn, while private equity and venture financing deals totalled $645.48m and $156.5m, respectively.
US medical devices industry deals in June 2020: Top deals
The top five medical devices industry deals accounted for 75.5% of the overall value during June 2020.
The combined value of the top five medical devices deals stood at $1.89bn, against the overall value of $2.5bn recorded for the month.
The top five medical devices industry deals of June 2020 tracked by GlobalData were:
1) InVitae’s $1.4bn acquisition of ArcherDx
2) The $200m asset transaction with CareZone by Walmart
3) First Round Capital, Foresite Capital Management, GV Management Co, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals and TPG Capital’s $100m private equity deal with DNAnexus
4) The $100m venture financing of Cue Health by ACME Capital, Decheng Capital, Foresite Capital Management, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners
5) LeMaitre Vascular’s acquisition of Artegraft for $90m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.